申请人:Schering Aktiengesellschaft
公开号:US04874768A1
公开(公告)日:1989-10-17
The disclosure relates to 1,2-substituted ergoline derivatives of general Formula I ##STR1## wherein X is an oxygen or sulfur atom, R.sup.1 is a lower alkyl group, R.sup.2 is halogen, acyl, a saturated or unsaturated lower alkyl group which can optionally be substituted by OR.sup.4 wherein R.sup.4 is hydrogen, lower alkyl, tetrahydropyranyl or cycloalkyl, or by an optionally substituted aryl residue, an S-R.sup.5 -group wherein R.sup.5 means a lower alkyl group which can optionally be substituted by aryl or an optionally substituted aryl residue, a ##STR2## wherein n=2 o4 3, or a --CHO-group, R.sup.3 is lower alkyl or acyl, and C.sub.9 -C.sub.10 is a CC-single or a CC-double bond, and the hydrogen atom in the 10-position is in the .alpha.-location if C.sub.9 -C.sub.10 is a CC-single bond, as well as the acid addition salts thereof. The compounds exhibit valuable pharmacological properties.
本发明涉及一般式I的1,2-取代的麦角酸衍生物,其中X是氧或硫原子,R1是较低的烷基基团,R2是卤素,酰基,饱和或不饱和的较低烷基基团,可以选择地被取代为OR4,其中R4是氢,较低的烷基,四氢吡喃基或环烷基,或由可选择地取代的芳基残基,S-R5-基团,其中R5表示可以选择地被芳基或可选择地取代的芳基残基取代的较低烷基基团,##STR2##其中n = 2或4 3,或--CHO基团,R3是较低烷基或酰基,C9-C10是CC-单键或CC-双键,如果C9-C10是CC-单键,则10-位置的氢原子位于α-位置,以及它们的酸加成盐。这些化合物具有有价值的药理学特性。